Strata Critical Medical, Inc. (SRTA) Fair Value 2026

SRTA · Medical Care Facilities ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-27, Strata Critical Medical, Inc. (SRTA) trades at $6.17, versus a $3.05 median fair value across its 2 active models — 50.6% below the current price. QOC: 6.5/10. Value Trap Risk: 46/100 (WARN). 2/13 models active.

Key Facts

Ticker
SRTA
Price
$6.17
Quality Score
6.5/10
Value Trap Risk
46/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

Is Strata Critical Medical, Inc. (SRTA) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Strata Critical Medical, Inc. (SRTA) appears overvalued as of : the median of 2 independent fair value estimates is $3.05, 50.6% below the current price of $6.17. Estimates range from $0.06 to $6.04. SRTA scores 6.5/10 on fundamental quality and 46/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. SRTA’s -50.6% gap is wider than that market norm, and the Medical Care Facilities sector median is -28.6%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Strata Critical Medical, Inc. Stock in 2026? →

What Fair Value Does Each Model Give SRTA?

2 Intrinsic Value Models vs. Current Price ($6.17)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $6.04 -2.1%
Relative · Low Conviction
 $0.06 -99.0%

All Models Active

All 2 models are displayed above.

What Is Strata Critical Medical, Inc. (SRTA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Strata Critical Medical, Inc. presents a highly debated valuation profile at its current price of $6.17. The median intrinsic value is estimated at $3.05 (-50.6% median upside), masking a wide model spread between the 0 bullish models and 1 bearish models. Model dispersion is worth noting: FTNN targets $6.04 (-2.1%), versus Regime Cross at $0.06 (-99.0%). This +96.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SRTA?

2 of 13 models are currently active for SRTA. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for SRTA is $3.05 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does SRTA Rank in Medical Care Facilities?

Among 60 Medical Care Facilities stocks, SRTA ranks #32 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

See all Most Undervalued Medical Care Facilities Stocks →

Strata Critical Medical, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is SRTA a Value Trap?

CirclFi's Value Trap algorithm assigns SRTA a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Strata Critical Medical, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Strata Critical Medical, Inc. earns a quality score of 6.5/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

The gap between the most bullish and bearish model spans +96.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SRTA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SRTA's 2 active models, average confidence is 7%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Strata Critical Medical, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Care Facilities Stocks Should You Also Analyze?

10 related Medical Care Facilities stocks with 13-model coverage

AVAHAveanna Healthcare Holdings Inc.QOC 6.7SGRYSurgery Partners, Inc.QOC 6.4CCELCryo-Cell International, Inc.QOC 6.7RHEPRegional Health Properties, Inc.QOC 6.2INNVInnovAge Holding Corp.QOC 6.7AIRSAirSculpt Technologies, Inc.QOC 6.1WWWW International, Inc.QOC 5.5NHCNational HealthCare CorporationQOC 8.7BTMDbiote Corp.QOC 7.7ADUSAddus HomeCare CorporationQOC 8.9

Read investment analysis: AVAH · SGRY · CCEL · RHEP · INNV · AIRS · WW · NHC · BTMD · ADUS

Which Other Stocks Have a Similar Quality Score to SRTA?

7 companies across all industries closest to SRTA’s Quality of Company score of 6.5/10.

NAVINavient CorporationQOC 6.5ARRARMOUR Residential REIT, Inc.QOC 6.5CLPTClearPoint Neuro, Inc.QOC 6.5NAIINatural Alternatives International, Inc.QOC 6.5RCATRed Cat Holdings, Inc.QOC 6.5BIDUBaidu, Inc.QOC 6.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NAVI · ARR · CLPT · NAII · RCAT · BIDU · NVDA

Where Does SRTA Sit in CirclFi's Medical Care Facilities Rankings?

SRTA is ranked against every other Medical Care Facilities stock CirclFi covers in each of these screens.

See all Medical Care Facilities stocks ranked →

What Else Do Investors Ask About Strata Critical Medical, Inc.’s Valuation?

What is Strata Critical Medical, Inc.'s intrinsic value in 2026?

CirclFi puts Strata Critical Medical, Inc. (SRTA)'s intrinsic value at $3.05 — the median of 2 independent model estimates as of 2026-08-27, ranging from $0.06 to $6.04. The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SRTA overvalued or undervalued right now?

At $6.17, 0 of 2 active models suggest SRTA may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $3.05, 50.6% below the current price of $6.17 — a consensus view that SRTA is overvalued. The assessment depends on which methodology best fits Strata Critical Medical, Inc.'s business model in Medical Care Facilities.

What does a Quality of Company score of 6.5 mean for SRTA?

Strata Critical Medical, Inc.'s QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SRTA?

CirclFi analyzes SRTA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is SRTA a value trap in 2026?

Strata Critical Medical, Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Strata Critical Medical, Inc. (SRTA) has a median fair value of $3.05 — 50.6% below the current price of $6.17 — as of 2026-08-27.” Source: circlfi.com/stock/SRTA/ · Methodology
Primary sources for this SRTA valuation
  • Financial statements: Strata Critical Medical, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001779128) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SRTA as of ; valuations recomputed .